Placental DNA methylation at term reflects maternal serum levels of INHA and FN1, but not PAPPA, early in pregnancy

BMC Medical Genetics

Volumn 16, Issue 1, 2015, Pages

  Wilson, Samantha L ^a,b   Blair, John D ^a,b,c   Hogg, Kirsten ^a,d   Langlois, Sylvie ^a,b   von Dadelszen, Peter ^a,b   Robinson, Wendy P ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

DNA methylation; Intrauterine growth restriction; Maternal serum screening; Placenta; Preeclampsia

Indexed keywords

BIOLOGICAL MARKER; FIBRONECTIN; INHIBIN; INHIBIN ALPHA; PREGNANCY ASSOCIATED PLASMA PROTEIN A; UNCLASSIFIED DRUG; FN1 PROTEIN, HUMAN; INHIBIN-ALPHA SUBUNIT;

ARTICLE; BIRTH WEIGHT; BODY MASS; CONTROLLED STUDY; DNA METHYLATION; FEMALE; FIRST TRIMESTER PREGNANCY; GENE EXPRESSION; GENETIC ASSOCIATION; GESTATIONAL AGE; HUMAN; MATERNAL BLOOD; MATERNAL SERUM; PLACENTA WEIGHT; PREDICTION; PREGNANCY OUTCOME; PROTEIN EXPRESSION; RISK ASSESSMENT; SECOND TRIMESTER PREGNANCY; THIRD TRIMESTER PREGNANCY; ADULT; BLOOD; CASE CONTROL STUDY; EARLY DIAGNOSIS; FETAL GROWTH RETARDATION; GENETICS; MALE; METABOLISM; NEWBORN; PLACENTA; PRE-ECLAMPSIA; PREGNANCY; PRENATAL DIAGNOSIS; TERM BIRTH;

ADULT; CASE-CONTROL STUDIES; DNA METHYLATION; EARLY DIAGNOSIS; FEMALE; FETAL GROWTH RETARDATION; FIBRONECTINS; HUMANS; INFANT, NEWBORN; INHIBINS; MALE; PLACENTA; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, SECOND; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PRENATAL DIAGNOSIS; TERM BIRTH;

EID: 84960092777     PISSN: None     EISSN: 14712350     Source Type: Journal    
DOI: 10.1186/s12881-015-0257-z     Document Type: Article

References (36)

1. Alberry M, Soothill P. Management of fetal growth restriction. Arch Dis Child Fetal Neonatal Ed. 2007;92(1):F62-7.
2. Magee LA, Helewa M, Moutquin JM, von Dadelszen P. Hypertension guideline committee, strategic training initiative in research in the reproductive health sciences (STIRRHS) scholars: diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. J Obstet Gynaecol Can. 2008;30(3 Suppl):S1-48.
3. Huang T, Hoffman B, Meschino W, Okun N. Prediction of adverse pregnancy outcomes by combinations of first and second trimester biochemistry markers used in the routine prenatal screening of down syndrome. Prenat Diagn. 2010;30(5):471-7.
4. Smith GC, Stenhouse EJ, Crossley JA, Aitken DA, Cameron AD, Connor JM. Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth. J Clin Endocrinol Metab. 2002;87(4):1762-7.
5. Ong CY, Liao AW, Spencer K, Munim S, Nicolaides KH. First trimester maternal serum free β human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications. BJOG. 2000;107(10):1265-70.
6. Bersinger NA, Smárason AK, Muttukrishna S, Groome NP, Redman CW. Women with preeclampsia have increased serum levels of pregnancy-associated plasma protein A (PAPP-A), inhibin A, activin A and soluble E-selectin. Hypertens Pregnancy. 2003;22(1):45-55.
7. Poon LC, Syngelaki A, Akolekar R, Lai J, Nicolaides KH. Combined screening for preeclampsia and small for gestational age at 11-13 weeks. Fetal Diagn Ther. 2013;33(1):16-27.
8. Audibert F, Boucoiran I, An N, Aleksandrov N, Delvin E, Bujold E, et al. Screening for preeclampsia using first-trimester serum markers and uterine artery Doppler in nulliparous women. Am J Obstet Gynecol. 2010;203(4):383. e1-383. e8.
9. Sitras V, Paulssen R, Leirvik J, Vartun A, Acharya G. Placental gene expression profile in intrauterine growth restriction due to placental insufficiency. Reprod Sci. 2009;16(7):701-11.
10. Sitras V, Paulssen R, Grønaas H, Leirvik J, Hanssen T, Vårtun Å, et al. Differential placental gene expression in severe preeclampsia. Placenta. 2009;30(5):424-33.
11. Smets EM, Visser A, Go AT, van Vugt JM, Oudejans C. Novel biomarkers in preeclampsia. Clin Chim Acta. 2006;364(1):22-32.
12. Tsai S, Hardison NE, James AH, Motsinger-Reif AA, Bischoff SR, Thames BH, et al. Transcriptional profiling of human placentas from pregnancies complicated by preeclampsia reveals disregulation of sialic acid acetylesterase and immune signalling pathways. Placenta. 2011;32(2):175-82.
13. Avila L, Yuen R, Diego-Alvarez D, Peñaherrera M, Jiang R, Robinson W. Evaluating DNA methylation and gene expression variability in the human term placenta. Placenta. 2010;31(12):1070-7.
14. Blair JD, Yuen RK, Lim BK, McFadden DE, Von Dadelszen P, Robinson WP. Widespread DNA hypomethylation at gene enhancer regions in placentas associated with early-onset preeclampsia. Mol Hum Reprod. 2013;19(10):697-708.
15. Nishizawa H, Ota S, Suzuki M, Kato T, Sekiya T, Kurahashi H, et al. Comparative gene expression profiling of placentas from patients with severe pre-eclampsia and unexplained fetal growth restriction. Reprod Biol Endocrinol. 2011;9:107.
16. Gurusinghe S, Wallace EM, Lim R. The relationship between Activin A and anti-angiogenic factors in the development of pre-eclampsia. Pregnancy Hypertens: An Int J Women's Cardiovas Health. 2014;4(1):3-6.
17. Hogg K, Blair JD, von Dadelszen P, Robinson WP. Hypomethylation of the LEP gene in placenta and elevated maternal leptin concentration in early onset pre-eclampsia. Mol Cell Endocrinol. 2013;367(1):64-73.
18. Yuen RK, Peñaherrera MS, von Dadelszen P, McFadden DE, Robinson WP. DNA methylation profiling of human placentas reveals promoter hypomethylation of multiple genes in early-onset preeclampsia. Eur J Hum Genet. 2010;18(9):1006-12.
19. Auer J, Camoin L, Guillonneau F, Rigourd V, Chelbi ST, Leduc M, et al. Serum profile in preeclampsia and intra-uterine growth restriction revealed by iTRAQ technology. J Proteome. 2010;73(5):1004-17.
20. Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH. Prediction of early, intermediate and late pre eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks. Prenat Diagn. 2011;31(1):66-74.
21. Novakovic B, Yuen RK, Gordon L, Penaherrera MS, Sharkey A, Moffett A, et al. Evidence for widespread changes in promoter methylation profile in human placenta in response to increasing gestational age and environmental/stochastic factors. BMC Genomics. 2011;12(1):529.
22. Tobi EW, Lumey LH, Talens RP, Kremer D, Putter H, Stein AD, et al. DNA methylation differences after exposure to prenatal famine are common and timing- and sex-specific. Hum Mol Genet. 2009;18(21):4046-53.
23. El-Maarri O, Becker T, Junen J, Manzoor SS, Diaz-Lacava A, Schwaab R, et al. Gender specific differences in levels of DNA methylation at selected loci from human total blood: a tendency toward higher methylation levels in males. Hum Genet. 2007;122(5):505-14.
24. Engel SM, Joubert BR, Wu MC, Olshan AF, Haberg SE, Ueland PM, et al. Neonatal genome-wide methylation patterns in relation to birth weight in the Norwegian Mother and Child Cohort. Am J Epidemiol. 2014;179(7):834-42.
25. Overgaard MT, Oxvig C, Christiansen M, Lawrence JB, Conover CA, Gleich GJ, et al. Messenger ribonucleic acid levels of pregnancy-associated plasma protein-A and the proform of eosinophil major basic protein: expression in human reproductive and nonreproductive tissues. Biol Reprod. 1999;61(4):1083-9.
26. Lawrence JB, Oxvig C, Overgaard MT, Sottrup-Jensen L, Gleich GJ, Hays LG. Yates JR,3rd, Conover CA: The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. Proc Natl Acad Sci U S A. 1999;96(6):3149-53.
27. Mosesson MW, Amrani DL. The structure and biologic activities of plasma fibronectin. Blood. 1980;56(2):145-58.
28. CLEMMENSEN I. Fibronectin and its role in connective tissue diseases. Eur J Clin Invest. 1981;11(3):145-6.
29. Manokhina I, Wilson SL, Robinson WP: Non-invasive nucleic-acid based approaches to monitor placental health and predict pregnancy-related complications. Am J Obs Gynecol 2015 (In Press).
30. Metzenbauer M, Hafner E, Hoefinger D, Schuchter K, Stangl G, Ogris E, et al. Three-dimensional ultrasound measurement of the placental volume in early pregnancy: method and correlation with biochemical placenta parameters. Placenta. 2001;22(6):602-5.
31. Audibert F, Friedman SA, Frangieh AY, Sibai BM. Clinical utility of strict diagnostic criteria for the HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome. Am J Obstet Gynecol. 1996;175(2):460-4.
32. Douglas KA, Redman CW. Eclampsia in the United Kingdom. BMJ. 1994;309(6966):1395-400.
33. Von Dadelszen P, Magee LA, Roberts JM. Subclassification of preeclampsia. Hypertens Pregnancy. 2003;22(2):143-8.
34. Kramer MS, Platt RW, Wen SW, Joseph KS, Allen A, Abrahamowicz M, et al. Fetal/infant health study group of the Canadian perinatal surveillance system: a new and improved population-based Canadian reference for birth weight for gestational age. Pediatrics. 2001;108(2):E35.
35. Bibikova M, Barnes B, Tsan C, Ho V, Klotzle B, Le JM, et al. High density DNA methylation array with single CpG site resolution. Genomics. 2011;98(4):288-95.
36. Hogg K, Price EM, Robinson WP. Improved reporting of DNA methylation data derived from studies of the human placenta. Epigenetics. 2014;9(3):333-7.